The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II (Alliance/A091802) randomized trial of avelumab plus cetuximab vs. avelumab alone in advanced cutaneous squamous cell carcinoma (cSCC).
 
Dan Zandberg
Consulting or Advisory Role - Bicara Therapeutics; Blueprint Medicines; Coherus Biosciences; Coherus Biosciences; InhibRx; Macrogenics; Merck; Prelude Therapeutics; Seagen
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); AVEO (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst)
 
Jacob Allred
No Relationships to Disclose
 
Ari Rosenberg
Stock and Other Ownership Interests - Privo Technologies
Consulting or Advisory Role - Astellas Pharma; Eisai; EMD Serono; Geovax Labs; Janssen; Nanobiotix; Novartis; RAPT Therapeutics; Regeneron; Vaccitech
Speakers' Bureau - Coherus Biosciences
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb/Celgene (Inst); EMD Serono (Inst); Hookipa Biotech (Inst); Janux Therapeutics (Inst); Pfizer (Inst); Purple Biotech (Inst)
 
John Kaczmar
Stock and Other Ownership Interests - HCA Healthcare (I)
Honoraria - The Scienomics Group; Triangle Insights Group
Consulting or Advisory Role - Coherus Biosciences; EMD Serono/Merck; PDS Biotechnology; Rakuten Medical
 
Paul Swiecicki
Honoraria - CDR-Life; Elevar Therapeutics; Elevar Therapeutics; Geovax Labs; Prelude Therapeutics; Remix Therapeutics; Seagen
Research Funding - Ascentage Pharma Group (Inst)
 
Ricklie Julian
Consulting or Advisory Role - BioAtla; Jazz Pharmaceuticals
Speakers' Bureau - Jazz Pharmaceuticals
Travel, Accommodations, Expenses - BioAtla
 
Andrew Poklepovic
Speakers' Bureau - Natera
 
Jessica Bauman
Consulting or Advisory Role - Delcath Systems (I); EMD Serono; Pfizer
Travel, Accommodations, Expenses - Delcath Systems (I)
 
Minh Phan
No Relationships to Disclose
 
Nabil Saba
Honoraria - Coherus Biosciences; EMD Serono; Exelixis; Fulgent Pharma; GlaxoSmithKline; Merck; Nanobiotix; Novartis; Surface Oncology; TOSK
Consulting or Advisory Role - Akeso Biopharma; Fulgent Pharma; Seagen
Research Funding - Bristol-Myers Squibb; Exelixis
Patents, Royalties, Other Intellectual Property - Springer textbook Royalty; Uptodate chapter writing and editing
Travel, Accommodations, Expenses - Merck
 
John Ellerton
No Relationships to Disclose
 
James Ohr
No Relationships to Disclose
 
Julia Cordes
No Relationships to Disclose
 
Alan Ho
Consulting or Advisory Role - AffyImmune Therapeutics; Coherus Biosciences; Eisai; Exelixis; Hookipa Biotech; InhibRx; Kura Oncology; Lepu Biopharma; Nested Therapeutics; Rgenta; Takeda
Speakers' Bureau - Mt. Sinai; Physicans' Education Resource
Research Funding - Astellas Pharma; AstraZeneca; Ayala Pharmaceuticals; Bayer; Bayer; BioAtla; Bristol-Myers Squibb; Daiichi; Eisai; Elevar Therapeutics; Elevar Therapeutics; Genentech/Roche; Hookipa Biotech; Kura Oncology; Merck; Novartis; OncC4; Poseida; Remix Therapeutics; Rgenta; TILT Biotherapeutics; Verastem
Patents, Royalties, Other Intellectual Property - LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN
 
Stephanie Berg
Honoraria - Aptitude Health; Curio Science
Consulting or Advisory Role - Eisai; Exelixis; Guardant Health; Natera; Pfizer; Zencor
 
Pamela Munster
Leadership - Alessa Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; AtlasMedx; Hap10; OnKure; Parthenon Therapeutics; RasCal
Honoraria - JNJ; Olema Pharmaceuticals; Parthenon Therapeutics
Consulting or Advisory Role - Alessa Therapeutics; AtlasMedx; Olema Pharmaceuticals; RasCal
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arch Oncology (Inst); Arvinas (Inst); Arvinas (Inst); Bliss Biopharmaceutical (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Cyteir; Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); IgM Biosciences (Inst); Immune Design (Inst); InventisBio (Inst); Merck (Inst); Novartis (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Sanofi (Inst); Seagen (Inst); Skorpion (Inst); Tempest Therapeutics (Inst); Xencor (Inst); Xynomic Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
Other Relationship - ABIM Subspecialty Board; NIH/NCI
 
Gary Schwartz
Stock and Other Ownership Interests - Bionaut Labs; GenCirq
Consulting or Advisory Role - Bionaut Labs; Concarlo; Ipsen; OnCusp Therapeutics; PTC Therapeutics; Ratiopharm
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy